RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells
- Sci Adv. 2024 Apr 19;10(16):eadi1782. doi: 10.1126/sciadv.adi1782.
- 1. Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.
- 2. Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
- 3. Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, PR China.
- 4. Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA.
- 5. Gehr Family Center for Leukemia Research, City of Hope Medical Center and Comprehensive Cancer Center, Duarte, CA 91010, USA.
- 6. Zhejiang University Cancer Center, Hangzhou, Zhejiang, PR China.
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that Necroptosis, a form of programmed cell death, contributed to the antileukemia activity of R-2HG. Mechanistically, R-2HG competitively inhibited the activity of lysine demethylase 2B (KDM2B), an α-ketoglutarate-dependent dioxygenase. KDM2B inhibition increased histone 3 lysine 4 trimethylation levels and promoted the expression of receptor-interacting protein kinase 1 (RIPK1), which consequently caused Necroptosis in AML cells. The expression of RIPK3 was silenced because of DNA methylation in IDH-mutant (mIDH) AML cells, resulting in R-2HG resistance. Decitabine up-regulated RIPK3 expression and repaired endogenous R-2HG-induced Necroptosis pathway in mIDH AML cells. Together, R-2HG induced RIPK1-dependent Necroptosis via KDM2B inhibition in AML cells. The loss of RIPK3 protected mIDH AML cells from Necroptosis. Restoring RIPK3 expression to exert R-2HG's intrinsic antileukemia effect will be a potential therapeutic strategy in patients with AML.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
-
-
target: CaspaseResearch Areas: Inflammation/Immunology
-
-